AMNIMO
amnimo Inc. (Headquarters: Musashino City, Tokyo; President & CEO: Koichi [Casey] Taniguchi; hereafter, “amnimo”) starts developing an industrial-use LTE gateway, “Edge Gateway,” which is equipped with rich computing resources and a high level of robustness.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200322005056/en/
IoT is a mechanism by which a variety of devices are connected to each other via the network or the cloud service; these devices exchange information with each other. Recently, numerous approaches to the use of industrial-use IoT (IIoT) have been evolving in all types of industries. As IIoT continues to proliferate, examples of user work process improvements are increasing, but at the same time, we are witnessing operational issues such as suppressing failures in harsh external environments and being able to remotely deal with failures without going to the site. There have also been requests to process large volumes of data, such as video, using Edge in an advanced manner.
To resolve such issues, amnimo is developing the “Edge Gateway,” which is optimized for IIoT. The objective is to equip the Edge Gateway with LTE communication features that can be used in a wide variety of industries; in particular, to develop an optimal design for use in surveillance-camera systems.
[Characteristics of the Edge Gateway]
- Wide operating temperature range and power voltage range. Equipped with power circuits that are robust against noise and sudden outages, it has features for automatic recovery in case of a failure. This helps achieve stable operation even in harsh outdoor environments.
- Equipped with 2 GB of RAM and 32 GB eMMC for program storage space as the standard configuration, it can also be operated using a 2-TB SSD (Solid State Drive), enabling large-volume video data to be stored within the Edge Gateway.
- Equipped with a power-supply function for PoE(*1) compatible devices, it can be directly connected to a maximum of four IP cameras without using a PoE hub.
- The communication modules can accommodate two types of plastic SIM cards and eSIMs for a maximum of four different carrier SIMs, enabling the user to bypass communication failures by switching SIMs at high speeds in cases of emergency.
- Customer app development is possible on the Ubuntu OS; in addition, software development kits are provided for partners.
- Equipped with a VMS (Video Management System (*2)) as standard, simplifying the process of constructing small-, medium-, and large-scale surveillance systems.
- An extension port slot is internally provided in the Edge Gateway, enabling smooth addition of future functional extensions.
*1 Power over Ethernet: Specification wherein power is provided to the connected device(s) using Ethernet communication cables.
*2 System for saving and managing video captured using a surveillance camera.
In addition, we are developing a “device management system” to resolve issues related to operation on IIoT devices, such as the Edge Gateway. This device management system is a cloud service that enables initial configuration of IIoT devices, remote configuration and firmware updates, management of installation location, equipment life monitoring, log collection during operation, problem analysis and replacement, and transfer of configuration data for troubleshooting, thereby reducing the burden on the operator.
amnimo provides customer support for IIoT service and surveillance-camera systems, with the following objectives: “fast response and resolution for customer issues,” “value creation and innovation,” and “aim to grow with partners.”
About amnimo
amnimo was formed as a solely owned subsidiary of Yokogawa Electric Corporation as a new business to provide Industrial Internet of Things (IIoT) services in May 2018. With an excellent mobility, amnimo makes a swift decision and develops its business in a rapidly changing market. amnimo strengthens collaboration with customers and partner companies in various fields and countries to create new shared values by leveraging IIoT technologies.
To learn more, please visit https://amnimo.com/en/
The company names, organization names, and product names used in the document are registered trademarks or trademarks of the relevant organizations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200322005056/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
